These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6147052)

  • 1. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
    Dammann HG; Müller P; Simon B; Kommerell B
    Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of Zollinger-Ellison syndrome with ranitidine.
    Vezzadini P; Bonora G; Tomassetti P; Pazzaglia M; Labò G
    Int J Tissue React; 1983; 5(4):339-43. PubMed ID: 6323334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of the hypersecretion of acid in Zollinger-Ellison syndrome (ZES)].
    Varas MJ; López A; Gordillo J
    Rev Esp Enferm Apar Dig; 1989 Apr; 75(4):419-20. PubMed ID: 2568007
    [No Abstract]   [Full Text] [Related]  

  • 7. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral famotidine on 24-hour intragastric acidity.
    Santana IA; Lanzon-Miller S; Pounder RE
    Postgrad Med J; 1986; 62 Suppl 2():39-42. PubMed ID: 2890150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [I.v. famotidine versus i.v. ranitidine: intragastric pH behavior in surgical intensive care patients].
    Friedl W; Krier C; Dammann HG; Müller P; Simon B
    Z Gastroenterol; 1985 Nov; 23(11):603-7. PubMed ID: 2868579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of ranitidine in the medical treatment of Zollinger-Ellison syndrome.
    Bonfils S; Mignon M; Vallot ; Mayeur S
    Scand J Gastroenterol Suppl; 1981 Jun; 69():119-23. PubMed ID: 6119775
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer.
    Savarino V; Mela GS; Scalabrini P; Di Timoteo E; Magnolia MR; Celle G
    Digestion; 1987; 37(2):103-9. PubMed ID: 3305114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Continuous recording of gastric pH to assess the efficacy of antisecretory drugs in Zollinger-Ellison syndrome].
    Galmiche JP; Mignon M; Ducrotte P; Mayeur S; Arsene D; Vallot T
    Nouv Presse Med; 1981 Feb; 10(6):432-3. PubMed ID: 6111787
    [No Abstract]   [Full Text] [Related]  

  • 15. [H2 receptor antagonists and intragastric acidity].
    Dammann HG; Walter TA; Müller P; Simon B
    Dtsch Med Wochenschr; 1984 Nov; 109(46):1767-9. PubMed ID: 6094136
    [No Abstract]   [Full Text] [Related]  

  • 16. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
    G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract]   [Full Text] [Related]  

  • 17. [The role of H2 antagonists in Zollinger-Ellison syndrome].
    Dammann HG; Walter TA; Müller P; Simon B
    Clin Ter; 1984 Dec; 111(5):393-400. PubMed ID: 6151434
    [No Abstract]   [Full Text] [Related]  

  • 18. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis against acid aspiration syndrome. Single oral dose of H2-antagonist on the evening before elective surgery.
    Gallagher EG; White M; Ward S; Cottrell J; Mann SG
    Anaesthesia; 1988 Dec; 43(12):1011-4. PubMed ID: 2906783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of oral famotidine and ranitidine on gastric volume and pH.
    Dubin SA; Silverstein PI; Wakefield ML; Jense HG
    Anesth Analg; 1989 Nov; 69(5):680-3. PubMed ID: 2572186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.